- Claimable, an AI startup, has helped patients reverse thousands of health insurance denials by automating the appeals process, according to a Bloomberg report published April 22, 2026.
- Mark Cuban — entrepreneur, investor, and co-founder of Cost Plus Drugs — is among the company’s backers.
- The startup targets a documented structural gap: fewer than 1% of denied U.S. health insurance claims are ever appealed, despite high overturn rates when appeals are filed.
- KFF analysis of CMS data found that ACA marketplace insurers denied roughly 17% of in-network claims in 2021, with some plans overturning more than 60% of challenged denials.
What Happened
Claimable, an AI-powered startup, has helped patients reverse thousands of denied health insurance claims, according to a Bloomberg feature published April 22, 2026. The company automates the generation of insurance appeal letters, allowing patients to contest insurer rejections of physician-ordered treatments without navigating the documentation and regulatory complexity that historically discourages most people from filing appeals. Mark Cuban — co-founder of the pharmaceutical venture Cost Plus Drugs and a prominent healthcare industry critic — is among the company’s backers.
Why It Matters
Health insurance denials became a focal point of public and regulatory attention in late 2024, following the killing of UnitedHealthcare CEO Brian Thompson in December of that year. Congressional hearings followed, intensifying scrutiny of prior authorization practices that critics have long argued delay or deny medically necessary care. That climate has increased investor and public interest in companies working to counterbalance insurer administrative power.
KFF analysis of CMS data found that ACA marketplace insurers denied roughly 17% of in-network claims in 2021. When patients did contest those decisions, some insurers overturned more than 60% of challenged denials — a figure that illustrates the asymmetry between insurers’ administrative capacity and the ability of most patients to mount effective appeals. Cuban’s involvement in Claimable follows his established pattern of targeting that kind of structural information gap. His Cost Plus Drugs pharmacy, launched in January 2022, dispensed generic medications at cost-plus-15% margins by bypassing pharmacy benefit managers, providing millions of prescriptions at prices substantially below traditional retail channels.
Technical Details
Claimable’s platform uses AI to generate insurance appeal letters calibrated to specific denial codes, plan-type requirements, and applicable state and federal regulations, according to Bloomberg’s reporting. The system is designed to reduce the manual research burden that makes appeals prohibitive for most patients: identifying relevant clinical evidence, citing applicable coverage policies, and formatting submissions to meet insurer-specific documentation requirements.
CMS data shows that fewer than 1% of denied health insurance claims in the U.S. are ever appealed by patients — meaning the gap between what patients could contest and what they actually contest is structurally large. Automating the drafting process removes a primary friction point: the need for patients to understand insurer-specific appeal pathways and construct medically and legally coherent arguments without professional assistance. The company’s reported success in reversing thousands of claims suggests the AI-generated letters are meeting the threshold insurers require to overturn initial decisions.
Who’s Affected
The direct beneficiaries are insured patients contesting denials for high-cost procedures, specialty drugs, and mental health services — categories that historically carry elevated denial rates. Patients with employer-sponsored coverage, ACA marketplace plans, and Medicaid managed care arrangements are all potentially within scope, depending on which plan types Claimable’s system supports. Self-insured employers that contract with insurers to administer benefits may also face downstream effects if successful appeals scale and shift cost exposure back to plans.
For health insurers, the pressure is two-directional: the direct financial cost of overturned denials, and increased regulatory scrutiny in an environment that has treated prior authorization reform as a legislative priority since 2024. If AI-assisted appeals become widespread, insurers may face structural pressure to revise denial criteria or accelerate deployment of their own AI-based claims-review systems.
What’s Next
Federal rules finalized in 2024 tightened prior authorization timelines for Medicare Advantage plans and expanded patient access to external appeals. Several states — including California and New York — have enacted or are advancing legislation applying similar standards to commercial insurance markets, creating a regulatory environment that is broadly more favorable to appeal-based interventions. Claimable’s growth will depend on how effectively it reaches patients at the moment they receive denial letters, and on whether insurers respond to increased appeal volumes by restructuring their internal review processes.
